IP Library Granted Patent US 9,914,695
Granted Patent B2
US 9,914,695 · App. 15/202,670 · Granted Mar 13, 2018

Two-step process for preparing 3-substituted phenylalkylamines

Inventors: Doug Teramura (Hazelwood, MO); Subo Liao (Hazelwood, MO)
Assignee: Mallinckrodt LLC
C07C213/02C07C45/69C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,695
App. No.
15/202,670
Granted
Mar 13, 2018
Kind
B2
Abstract

Processes for preparing 3-substituted phenylalkylamines comprising reacting a phenyl boronic compound with an α-β unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction, followed by reductive alkylation. The processes may be useful in the synthesis of tapentadol.

Claims (39)

1. A process for preparing a compound of Formula (III), the process comprising:

a) contacting a compound of Formula (I) with a compound of Formula (IV) in the presence of a transition metal catalyst and a chiral ligand to form a compound of Formula (II); and

b) contacting the compound of Formula (II) with a secondary amine having Formula (V) to form the compound of Formula (III) according to the following reaction scheme:

wherein:

R is hydrogen, alkenyl, substituted alkenyl, aryl, or substituted aryl;

R 1 is hydrogen, OR 20 , NR 20 R 21 , SR 20 R 21 , hydrocarbyl, or substituted hydrocarbyl;

R 2 is hydrocarbyl or substituted hydrocarbyl;

R 3 , R 4 , R 5 , and R 7 are independently hydrogen, OR 20 , NR 20 R 21 , SR 20 R 21 , halo, hydrocarbyl, or substituted hydrocarbyl;

R 8 is

 —O—(CR 13 R 14 ) n —O—, —O—B—O—B—O—, or trihalo;

R 10 and R 11 are independently hydrocarbyl, substituted hydrocarbyl, or R 10 and R 11 together may form a ring or ring system selected from carbocyclic, heterocyclic, aryl, heteroaryl, or combinations thereof;

R 12 is hydrocarbyl or substituted hydrocarbyl;

R 13 and R 14 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 20 and R 21 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; and

n is an integer of 1 or greater.

2. The process of claim 1 , wherein R is hydrogen, C 1 -C 10 alkenyl, substituted C 1 -C 10 alkenyl, aryl, substituted aryl, or aryl(C 1 -C 10 )alkyl; R 1 is hydrogen, alkyl, or substituted alkyl; R 2 and R 12 are independently alkyl or substituted alkyl; R 3 , R 4 , R 5 , and R 7 are independently hydrogen, alkyl, substituted alkyl, hydroxyl, alkoxy, substituted alkoxy, aryl, substituted aryl, alkylaryl, or substituted alkylaryl; R 10 and R 11 are independently alkyl or substituted alkyl; and R 13 and R 14 are independently hydrogen, alkyl, aryl, alkylaryl, or organoborane.

3. The process of claim 2 , wherein R is hydrogen or benzyl; R 1 is hydrogen; R 2 and R 12 are independently C 1 -C 10 alkyl; each of R 3 , R 4 , R 5 , and R 7 is hydrogen; and R 10 and R 11 are independently C 1 -C 10 alkyl.

4. The process of claim 1 , wherein the compound of Formula (I) is 3-hydroxyphenylboronic acid, 3-hydroxyphenyl trifluoroborate, 3-hydroxyphenylboronic acid pinacol ester, 3-hydroxyphenylboronic ester, derived from 3-hydroxyphenylboroxine, 3-benzyloxyphenylboronic acid, 3-benzyloxyphenyl trifluoroborate, 3-benzyloxyphenylboronic acid pinacol ester, 3-benzyloxyphenylboronic ester, or is derived from 3-benzyloxyphenylboroxine.

5. The process of claim 1 , wherein the compound of Formula (I) and the compound of Formula (IV) are present at a molar ratio of about 1:0.5 to about 1:6.0.

6. The process of claim 1 , wherein the transition metal catalyst comprises rhodium, palladium, or ruthenium; and the compound of Formula (I) and the transition metal catalyst are present at a molar ratio of about 1:0.0001 to about 1:0.1.

7. The process of claim 1 , wherein the chiral ligand is a bicyclic chiral diene; and the transition metal catalyst and the chiral ligand are present at a weight ratio of about 1:0.5 to about 1:2.

8. The process of claim 1 , wherein step (a) further comprises contact with a secondary or a tertiary amine; and the compound of Formula (I) and the secondary or tertiary amine are present at a molar ratio of about 1:0.01 to about 1:1.0.

9. The process of claim 8 , further comprising contact with a proton acceptor; and the compound of Formula (I) and the proton acceptor are present at a molar ratio of about 1:0.001 to about 1:2.0.

10. The process of claim 1 , wherein step (a) is conducted in the presence of a solvent chosen from a polar protic solvent, a polar aprotic solvent, a non-polar solvent, or a combination thereof; and the solvent and the compound of Formula (I) are present at a volume to weight ratio of about 1.0:1 to about 50:1; and step (a) is conducted at a temperature from about −10° C. to about 80° C.

11. The process of claim 10 , wherein the compound of Formula (II) is obtained in a yield of at least about 25%.

12. The process of claim 1 , wherein the compound of Formula (II) and the compound of Formula (V) are present at molar ratio of about 1:1 to about 1:20; step (b) is conducted in the presence of a reducing agent; and step (b) is conducted at a temperature from about −10° C. to about 80° C.

13. The process of claim 1 , wherein R is hydrogen or benzyl; R 1 is hydrogen; R 2 is ethyl; each of R 3 , R 4 , R 5 , and R 7 is hydrogen; and each of R 10 , R 11 , and R 12 is methyl.

14. The process of claim 13 , wherein the transition metal catalyst is [RhCl(C 2 H 4 ) 2 ] 2 and the chiral ligand is (1S,4S)-2,5-diphenylbicyclo[2,2,2]octa-2,5-diene.

15. The process of claim 14 , wherein the compound of Formula (III) is 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl] phenol.

16. A process for preparing a compound of Formula (IIa), the process comprising contacting a compound of Formula (Ia) with a compound of Formula (IVa) in the presence of a catalyst to give the compound of Formula (IIa):

wherein:

Z is a boron containing moiety;

R is hydrogen, alkenyl, substituted alkenyl, aryl, substituted aryl, or arylalkyl;

R 3 , R 4 , R 5 , and R 7 are independently hydrogen, OR 20 , NR 20 R 21 , SR 20 R 21 , halo, hydrocarbyl, or substituted hydrocarbyl; and

R 20 and R 21 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl.

17. The process of claim 16 , wherein the transition metal catalyst comprises rhodium; and the chiral ligand is a bicyclic chiral diene.

18. The process of claim 16 , further comprising contact with an amine.

19. The process of claim 18 , further comprising contact with a proton acceptor.

20. The process of claim 16 , wherein R is hydrogen or benzyl; each of R 3 , R 4 , R 5 , and R 7 is hydrogen, and; the transition metal catalyst is [RhCl(C 2 H 4 ) 2 ] 2 ; and the chiral ligand is (1S,4S)-2,5-diphenylbicyclo[2,2,2]octa-2,5-diene.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0124 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0375 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2017
From: TERAMURA, DOUG; LIAO, SUBO
To: MALLINCKRODT LLC
Reel/Frame 042141/0408 →
Continuity (2)
Provisional Application 62190975 · Jul 10, 2015
Related Publication 20170008832A1 · Jan 12, 2017